CN109824617A - A kind of Linezolid impurity M1Z1 and its preparation method and application - Google Patents
A kind of Linezolid impurity M1Z1 and its preparation method and application Download PDFInfo
- Publication number
- CN109824617A CN109824617A CN201910116572.9A CN201910116572A CN109824617A CN 109824617 A CN109824617 A CN 109824617A CN 201910116572 A CN201910116572 A CN 201910116572A CN 109824617 A CN109824617 A CN 109824617A
- Authority
- CN
- China
- Prior art keywords
- compound
- linezolid
- impurity
- synthetic method
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a kind of Linezolid degradation impurity M1Z1, as shown in Equation 1.In addition, also disclosing the synthetic method of the impurity, the method includes being starting material with compound 2, its final products is obtained through elimination reaction.Linezolid degradation impurity M1Z1 of the invention may be used as the reference substance of drug quality control and its research.
Description
Technical field
The invention belongs to but be not limited to field of medicinal chemistry, in particular to a kind of Linezolid impurity M1Z1 and its
Preparation method and purposes.
Background technique
Linezolid (linezolid), entitled Isosorbide-5-Nitrae-dihydro -1,6- dimethyl -4- (3- nitrotoleune) -3, the 5- pyrrole of chemistry
Pyridine dicarboxyl -2 [4- (benzhydryl) -1- piperazinyl] ethyl methyl esters dihydrochloride, is a kind of lipophilic third generation dihydro pyrrole
Pyridine class and the calcium ion binary channels retarding agent for having L-type, T-type concurrently.
The medicine still has some adverse reactions in clinical application at present, and if it is related with impurity, up for studying and tracking
Relevant research report, but pass through the quality of strict control Linezolid, it improves quality standard and is expected to reduce the bad of the drug
Reaction.
Summary of the invention
It is the general introduction to the theme being described in detail herein below.This general introduction is not the protection model in order to limit claim
It encloses.
Inventor developed a kind of Linezolid impurity and its production method, the Linezolid obtained by this method is miscellaneous
Matter purity is more than 99%, and reaction preparation condition is simple (being raw material with commercially common Linezolid starting material), and technique
Stablize, it is easily operated.
The present invention provides a kind of Linezolid impurity M1Z1, chemical structure is as shown in Equation 1:
On the other hand, the present invention provides the synthetic method of Linezolid impurity M1Z1 a kind of, include the following steps:
Elimination reaction occurs for compound 2, obtains Linezolid impurity M1Z1 i.e. compound 1;
In the synthetic method of the application, wherein the compound 2 can be compound 2 ' or compound 2 " or
The mixture of person's compound 2 ' and compound 2 ":
In the synthetic method of the application, wherein elimination reaction is in aprotic organic solvent and in weak base, high temperature
Lower progress.
In above-mentioned synthetic method, wherein the aprotic organic solvent is dimethylformamide, that is, DMF, diformazan
One of yl acetamide, dioxane and toluene, it is preferable that be dimethylformamide.
In above-mentioned synthetic method, wherein the weak base be weak base be triethylamine, potassium phthalimide, pyridine,
Or diisopropyl ethyl amine (DIPEA), it is preferable that be triethylamine.
In above-mentioned synthetic method, wherein the molar ratio of the compound 2 and weak base is 1:3-6.
In above-mentioned synthetic method, wherein the mass volume ratio of the compound 2 and aprotic organic solvent is 1:5-
10;(unit g:mL).
In above-mentioned synthetic method, wherein the high temperature of the generation elimination reaction is 85~120 DEG C, it is preferable that is
100~115 DEG C.
In above-mentioned synthetic method, optionally, using heating so that compound 2 is dissolved in aprotic organic solvent,
Here, the temperature of heating for dissolving is 50~90 DEG C, it is preferable that is 65~85 DEG C.
In a kind of synthetic method of the application, which includes will be molten in the addition dimethylformamide of compound 2
Then triethylamine or potassium phthalimide is added and heat up 85~95 DEG C, stirring in solution;It is anti-to be performed under heating conditions elimination
It answers;The reaction system is added to the water by end of reaction, and then stirring adds methylene chloride (DCM), water phase is abandoned in liquid separation, will have
Machine is mutually concentrated under reduced pressure, and obtains Linezolid degradation impurity i.e. compound 1.
In above-mentioned synthetic method, wherein the triethylamine or potassium phthalimide of the compound 2 and addition
Molar ratio is 1:3-6;
The mass volume ratio of the compound 2 and the DMF being added are 1:5-10;(unit g:mL);
The mass volume ratio of the compound 2 and the water being added is 1:5-10;(unit g:mL);
The mass volume ratio of the compound 2 and the extractant DCM being added are 1:10-20;(unit g:mL).
The third aspect, the present invention provides above-mentioned Linezolid impurity M1Z1 in Linezolid bulk pharmaceutical chemicals or its preparation
Purposes in quality research or quality control as reference substance.
Invention resulting product purity is higher, and the five-membered ring of product can be destroyed by overcoming traditional dehalogenate technique
Structure.
Other features and advantages of the present invention will be illustrated in the following description, also, partly becomes from specification
It obtains it is clear that understand through the implementation of the invention.The objectives and other advantages of the invention can be by specification and power
Specifically noted structure is achieved and obtained in sharp claim.
Specific embodiment
It, hereinafter will be to the embodiment of the present invention for the purposes, technical schemes and advantages of the application are more clearly understood
It is described in detail.It should be noted that in the absence of conflict, the features in the embodiments and the embodiments of the present application can
With mutual any combination.
In the embodiment of the present application, reagent used is all commercially to buy.
Bruker-400MHz Nuclear Magnetic Resonance (solvent DMSO, TMS are internal standard)
The instrument model of MS: Waters ACQUITY UPLC H-Class;
Carbon-13 nmr spectra (13C-NMR): III -400M nuclear magnetic resonance chemical analyser of Bruker Avance;100MHz, solvent:
DMSO-d6。
The instrument model of HPLC: Agilent 1260
The testing conditions of HPLC are as follows:
Chromatographic column: welch vltimate XB-C18 (3 μm, 4.6mm × 250mm);
Detector: UV,
Detection wavelength: 254nm;
Column temperature: 40 DEG C;
Flow velocity: 0.8mL/min;
Sample volume: 10 μ L.
Mobile phase: 0.1mol/L trifluoroacetic acid aqueous solution: 0.1mol/L trifluoroacetic acid acetonitrile solution
Embodiment 1
The preparation of Linezolid impurity M1Z1
Compound 2 ' (10.0g) is added in DMF (50ml) and is dissolved at 70 DEG C, triethylamine is added after dissolved clarification
(10.0g) is warming up to 85 DEG C, magnetic agitation 10h, 90 DEG C of reaction temperature.After completion of the reaction, DCM is added in the reaction system
(100ml) extraction, organic phase are concentrated under reduced pressure at 45 DEG C.Off-white powder (compound 1) 8.5g is obtained, molar yield:
96.04%.Mass spectrum m+1/z=279, HPLC purity is 99.5%.
Embodiment 2
The preparation of Linezolid impurity M1Z1
Compound 2 ' (10.0g) is added in DMF (50ml) and is dissolved at 70 DEG C, it is sub- that phthalyl is added after dissolved clarification
Amine potassium (10.0g) is warming up to 90 DEG C, magnetic agitation 10h, 110 DEG C of reaction temperature.After completion of the reaction, water (100ml) is added to be quenched, to
DCM (100ml) extraction is added in system, organic phase is concentrated under reduced pressure at 45 DEG C.Column chromatography for separation obtains off-white powder (chemical combination
Object 1) 2.5g, molar yield: 96.04%.Mass spectrum m+1/z=279, HPLC purity is 99.1%.
Serial number | RT(min) | Peak area | Peak area % | Peak width (sec) | Peak height |
1. | 50.020 | 59663 | 0.781 | 45.600 | 3372 |
2. | 51.243 | 7571376 | 99.142 | 57.200 | 615596 |
3. | 54.950 | 5847 | 0.077 | 17.600 | 1110 |
Mp:297 DEG C;1H-NMR(400MHz,DMSO-d6) δ (ppm): 7.48~7.60 (d, 1H, AR-H), 7.2 (t, 1H,
AR-H), 7.1 (d, 1H, AR-H), 4.9 (d, 2H ,-CH2- N), 4.5 (m, 2H ,-CH2), 3.75 (t, 4H ,-CH2-O-CH2),
2.9(t,4H,-CH2-N-CH2-)。
13C-NMR
The carbon atoms numbered of Linezolid impurity M1Z1
The carbon-13 nmr spectra data and ownership of Linezolid impurity M1Z1
Although embodiment disclosed by the application is as above, the content only for ease of understanding the application and use
Embodiment is not limited to the application.Technical staff in any the application fields, is taken off not departing from the application
Under the premise of the spirit and scope of dew, any modification and variation, but the application can be carried out in the form and details of implementation
Scope of patent protection, still should be subject to the scope of the claims as defined in the appended claims.
Claims (10)
1. a kind of Linezolid impurity M1Z1, chemical structure are as shown in Equation 1:
2. the synthetic method of Linezolid impurity M1Z1 as described in claim 1, includes the following steps:
Elimination reaction occurs for compound 2, obtains Linezolid impurity M1Z1 i.e. compound 1;
3. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 2, wherein 2 can be of compound
Close the mixture of object 2 ' or compound 2 " or compound 2 ' and compound 2 ":
4. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 2 or claim 3, wherein elimination reaction is non-proton
It is carried out in organic solvent and under weak base, high temperature.
5. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 4, wherein the aprotic organic solvent is
One of dimethylformamide, that is, DMF, dimethyl acetamide, dioxane and toluene, it is preferable that be dimethylformamide.
6. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 4, wherein the weak base is that weak base is three second
Amine, potassium phthalimide, pyridine or diisopropyl ethyl amine (DIPEA), it is preferable that be triethylamine.
7. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 4, wherein the height of the generation elimination reaction
Temperature is 85~120 DEG C, it is preferable that is 100~115 DEG C.
8. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 2, the synthetic method include that compound 2 is added
It is dissolved in dimethylformamide, triethylamine or potassium phthalimide is then added and heat up 85~95 DEG C, stirring;It is heating
Under the conditions of carry out elimination reaction;The reaction system is added to the water by end of reaction, then stirring adds methylene chloride, liquid separation
Water phase is abandoned, organic phase is concentrated under reduced pressure, Linezolid degradation impurity i.e. compound 1 is obtained.
9. the synthetic method of Linezolid impurity M1Z1 as claimed in claim 8, wherein the compound 2 and the three of addition
The molar ratio of ethamine or potassium phthalimide is 1:3-6;
The mass volume ratio of the compound 2 and the DMF being added are 1:-10;(unit g:mL);
The mass volume ratio of the compound 2 and the water being added is 1:5-10;(unit g:mL);
The mass volume ratio of the compound 2 and the extractant DCM being added are 1:10-20;(unit g:mL).
10. Linezolid impurity M1Z1 described in claim 1 Linezolid bulk pharmaceutical chemicals or its preparation quality research or
Purposes in quality control as reference substance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910116572.9A CN109824617A (en) | 2019-02-13 | 2019-02-13 | A kind of Linezolid impurity M1Z1 and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910116572.9A CN109824617A (en) | 2019-02-13 | 2019-02-13 | A kind of Linezolid impurity M1Z1 and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109824617A true CN109824617A (en) | 2019-05-31 |
Family
ID=66863672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910116572.9A Pending CN109824617A (en) | 2019-02-13 | 2019-02-13 | A kind of Linezolid impurity M1Z1 and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109824617A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279054A (en) * | 2011-02-24 | 2017-01-04 | 李药业有限公司 | Linezolid and the new preparation process of new intermediate thereof |
-
2019
- 2019-02-13 CN CN201910116572.9A patent/CN109824617A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279054A (en) * | 2011-02-24 | 2017-01-04 | 李药业有限公司 | Linezolid and the new preparation process of new intermediate thereof |
Non-Patent Citations (3)
Title |
---|
K.V.S.R. KRISHNA REDDY等: ""Isolation and characterization of process-related impurities in linezolid"", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
张志国等: ""利奈唑胺降解杂质的合成研究"", 《中国药物化学杂质》 * |
林晓兵: ""HPLC 法测定利奈唑胺原料药中有关物质的含量"", 《科学时代》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE030685T2 (en) | Macrocyclic purines for the treatment of viral infections | |
JP2021514967A (en) | Crystal type, salt type and method for producing the pyridinoimidazole compound | |
CN105367486A (en) | New impurity of cinitapride tartrate and preparation method and application thereof | |
CN104557887A (en) | 1,8-naphthalimide derivative as well as synthesis method and application thereof | |
CN106905319B (en) | Preparation method of substituted benzenesulfonyl kuhseng butane or hydrochloride thereof | |
CN107602557A (en) | A kind of nitrogen mustards rutaecarpin derivative and its production and use | |
CN107674076A (en) | One kind has the preparation method and purposes of the rutaecarpin split nitrogen mustard derivatives of antitumor activity | |
CN109824617A (en) | A kind of Linezolid impurity M1Z1 and its preparation method and application | |
WO2017103587A1 (en) | Substituted naphthalene diimides and their use | |
CN104829619B (en) | A kind of substituted aryl matrine compound and preparation method and application | |
CN103435560B (en) | Synthesis and application of aceanthrylene [1,2-b] quinoxaline derivative with flexible side chain | |
CN109134380A (en) | Chloro aminooimidazole class compound and preparation method thereof, purposes and detection method | |
CN109180583B (en) | Synthesis and application of naphthalimide derivative containing heterocyclic sulfone group and N-oxide | |
Wu et al. | Synthesis and biological activities of fluorinated 10-hydroxycamptothecin and SN38 | |
CN102731396A (en) | Polyamine naphthalimide compounds and application of same in preparation of pharmaceutical preparation | |
ES2346215T3 (en) | PROCEDURE TO PREPARE 2-CIANO-3-HYDROXI-N- (PHENYL) BUT-2-ENAMIDAS. | |
CN106902123B (en) | Application of 5-hydro-1, 4-benzodiazepine compound in treating liver cancer | |
CN107353287B (en) | A kind of quinoxaline and heterocyclic fourth ketone compounds and its application in antitumor | |
CN103951603B (en) | A kind of compound with three indole structure and its preparation method and application | |
CN104800228B (en) | A kind of application of O- benzoyl-(4- trifluoromethyl) salicylamide compound in preparation treatment bowelcancer medicine | |
CN104230787A (en) | N-(1,3-dioxoisoindoline) aryl amide compound as well as preparation method and applications of N-(1,3-dioxoisoindoline) aryl amide compound | |
CN109574866A (en) | A kind of preparation method of 2,6- dimethyl benzene amine long-chain compound | |
CN115340530B (en) | Method for preparing nitrogen-containing heterocyclic derivative and application thereof | |
CN111386268A (en) | Crystal form of URAT1 inhibitor and preparation method thereof | |
CN111620875B (en) | Preparation process of imidazopyrazine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190531 |